- Home
- NAD vs BEAM Comparison
NAD vs BEAM Comparison
Compare NAD & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAD
- BEAM
- Stock Information
- Founded
- NAD 1999
- BEAM 2017
- Country
- NAD United States
- BEAM United States
- Employees
- NAD N/A
- BEAM N/A
- Industry
- NAD Investment Managers
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NAD Finance
- BEAM Health Care
- Exchange
- NAD Nasdaq
- BEAM Nasdaq
- Market Cap
- NAD 2.8B
- BEAM 2.6B
- IPO Year
- NAD N/A
- BEAM 2020
- Fundamental
- Price
- NAD $11.94
- BEAM $26.00
- Analyst Decision
- NAD
- BEAM Strong Buy
- Analyst Count
- NAD 0
- BEAM 11
- Target Price
- NAD N/A
- BEAM $49.40
- AVG Volume (30 Days)
- NAD 595.7K
- BEAM 2.6M
- Earning Date
- NAD 01-01-0001
- BEAM 11-05-2025
- Dividend Yield
- NAD 4.35%
- BEAM N/A
- EPS Growth
- NAD N/A
- BEAM N/A
- EPS
- NAD N/A
- BEAM N/A
- Revenue
- NAD N/A
- BEAM $60,272,000.00
- Revenue This Year
- NAD N/A
- BEAM N/A
- Revenue Next Year
- NAD N/A
- BEAM $19.01
- P/E Ratio
- NAD N/A
- BEAM N/A
- Revenue Growth
- NAD N/A
- BEAM N/A
- 52 Week Low
- NAD $9.56
- BEAM $13.53
- 52 Week High
- NAD $11.64
- BEAM $35.25
- Technical
- Relative Strength Index (RSI)
- NAD 63.72
- BEAM 50.68
- Support Level
- NAD $11.71
- BEAM $25.80
- Resistance Level
- NAD $11.96
- BEAM $28.71
- Average True Range (ATR)
- NAD 0.08
- BEAM 1.96
- MACD
- NAD 0.00
- BEAM -0.35
- Stochastic Oscillator
- NAD 92.00
- BEAM 30.77
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.